Taleb BA. Tumour flare reaction in cancer treatments: a comprehensive literature review. Anticancer Drugs. 2019;30:953–8.

Article  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.

Article  PubMed  PubMed Central  Google Scholar 

Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy. Lancet Oncol. 2020;21:e463–76.

Article  CAS  PubMed  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of immunotherapy-related toxicities. J Natl Compr Canc Netw. 2019;17:255–89.

Article  CAS  PubMed  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.

Article  CAS  PubMed  Google Scholar 

Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, et al. Consensus recommendations on the management of toxicity associated with CD3 × CD20 bispecific antibody therapy. Blood. 2024;143:1565–75.

Article  CAS  PubMed  Google Scholar 

de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38:326–33.

Article  PubMed  Google Scholar 

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3 × CD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a Phase I/II trial. J Clin Oncol. 2023;41:2238–47.

Article  CAS  PubMed  Google Scholar 

Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398:1157–69.

Article  CAS  PubMed  Google Scholar 

Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023;114:4643–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39:1959–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sortais C, Cordeil S, Bourbon E, Idlhaj M, Ferrant E, Safar V, et al. Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. Leuk Lymphoma. 2023;64:707–11.

Article  CAS  PubMed  Google Scholar 

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259–75.

Article  CAS  PubMed  Google Scholar 

Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489–96.

Article  CAS  PubMed  Google Scholar 

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.

Article  CAS  PubMed  Google Scholar 

Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356–71.

Article  CAS  PubMed  Google Scholar